RNA Interference Therapeutics
Africa · 2 shared keywords
Updated
Reviewed by Vidhi Upadhyay
Africa Regenerative Medicine Market Industry Trends and Forecast to 2034: Segmented by (Product, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$3.11 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $726.4 Mn | — | — |
| 2025 (base) | $860.8 Mn | +$134.4 Mn | — |
| 2026 (forecast) | $1.02 Bn | +$159.2 Mn | +18.5% |
| 2027 (forecast) | $1.21 Bn | +$188.7 Mn | +40.4% |
| 2028 (forecast) | $1.43 Bn | +$223.6 Mn | +66.4% |
| 2029 (forecast) | $1.70 Bn | +$265.0 Mn | +97.2% |
| 2030 (forecast) | $2.01 Bn | +$314.0 Mn | +133.7% |
| 2031 (forecast) | $2.38 Bn | +$372.1 Mn | +176.9% |
| 2032 (forecast) | $2.82 Bn | +$440.9 Mn | +228.1% |
| 2033 (forecast) | $3.35 Bn | +$522.5 Mn | +288.8% |
| 2034 (forecast) | $3.97 Bn | +$619.2 Mn | +360.7% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $860.8 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $3.97 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 18.5% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Product, application and end user (see all) |
| Key players | Gilead Sciences, Inc., Novartis AG, Vertex Pharmaceuticals, Smith & Nephew, Organogenesis and 1 more (see all) |
| Regulator in Africa | AMASource: African Union, African Medicines Agency treaty. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Regenerative medicine aims to repair or replace damaged cells, tissues and organs using stem cells, gene therapy and engineered tissue.
Key segments of the regenerative medicine market include product (Cell Therapies, Gene Therapies and Tissue-Engineered Products) and application (Orthopedics, Cardiovascular and Dermatology).
Ageing populations, more chronic disease, broader access to medicines and steady new drug approvals are driving the regenerative medicine market.
Personalized treatments, local manufacturing and new technologies for making medicines give the regenerative medicine market room to grow.
Price controls, long and costly development, patent expiries and strict quality rules hold back the regenerative medicine market.
The regenerative medicine market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
The African Medicines Agency (AMA), set up by an African Union treaty in force since November 2021, aims to bring the work of national regulators together.[1] In some of the countries we cover here, medicines are approved by EDA (Egypt)[2], PPB (Kenya)[3], SAHPRA (South Africa)[4] and NAFDAC (Nigeria)[5]. How care is paid for in some of these countries: universal health insurance (Egypt)[6], the SHA (Kenya)[7], planned National Health Insurance (South Africa)[8] and out of pocket and the NHIA (Nigeria)[9].
[1] African Union, African Medicines Agency treaty. Checked 14 Nov 2026.
[2] Egyptian Drug Authority. Checked 14 Nov 2026.
[3] Pharmacy and Poisons Board. Checked 14 Nov 2026.
[4] South African Health Products Regulatory Authority. Checked 14 Nov 2026.
[5] NAFDAC. Checked 19 Nov 2026.
[6] Universal Health Insurance Authority. Checked 14 Nov 2026.
[7] Social Health Authority. Checked 14 Nov 2026.
[8] National Department of Health. Checked 14 Nov 2026.
[9] National Health Insurance Authority (NHIA). Checked 19 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for regenerative medicine. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Africa.
From our blog
Africa · 2 shared keywords
Africa · 2 shared keywords
Africa · 2 shared keywords
Africa · 2 shared keywords
Africa · 1 shared keyword
Africa · 1 shared keyword
Digital Health · Africa
Medical Devices · Africa
OTC & Nutraceuticals · Africa
Healthcare Services · Africa
OTC & Nutraceuticals · Africa
OTC & Nutraceuticals · Africa